Quince Therapeutics (NASDAQ:QNCX) Receives Overweight Rating from Cantor Fitzgerald

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued on Tuesday,Benzinga reports. They currently have a $70.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 105.16% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Oppenheimer began coverage on Quince Therapeutics in a research report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 price target for the company. Weiss Ratings raised shares of Quince Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Zacks Research upgraded shares of Quince Therapeutics to a “hold” rating in a research note on Wednesday, June 24th. Lifesci Capital upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Monday, June 29th. Finally, Wall Street Zen raised shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $308.00.

Quince Therapeutics Stock Performance

QNCX stock opened at $34.12 on Tuesday. The business has a 50-day simple moving average of $21.29 and a two-hundred day simple moving average of $29.32. The company has a market capitalization of $34.80 million, a P/E ratio of -0.22 and a beta of 1.36. Quince Therapeutics has a 52-week low of $15.10 and a 52-week high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last posted its earnings results on Friday, August 14th. The company reported ($12.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($28.02) by $15.71. As a group, sell-side analysts forecast that Quince Therapeutics will post -2.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Quince Therapeutics

Several large investors have recently modified their holdings of QNCX. XTX Topco Ltd bought a new stake in shares of Quince Therapeutics in the 2nd quarter worth approximately $37,000. Nantahala Capital Management LLC purchased a new stake in Quince Therapeutics in the second quarter worth $4,172,000. Bridgeway Capital Management LLC raised its stake in shares of Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after buying an additional 22,200 shares during the period. Vanguard Group Inc. lifted its position in shares of Quince Therapeutics by 21.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock valued at $2,874,000 after buying an additional 309,349 shares during the last quarter. Finally, ADAR1 Capital Management LLC grew its stake in shares of Quince Therapeutics by 442.1% during the 3rd quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock worth $1,263,000 after acquiring an additional 632,076 shares during the period. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.